anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Quaternized hemp seed oil is incorporated into cosmetic compositions, such as shampoos, hair conditioners, hair sprays, mousses, gel or sculpting lotions, pomades, and skin creams and lotions. The hemp seed oil is saponified and quaternized under gentle conditions, and in the substantial absence of oxygen, to avoid oxidation and cross-linking of essential fatty acids that provide biological benefit to the hair and skin. In a disclosed embodiment, saponification occurs in the presence of an alkali hydroxide catalyst, under a blanket of nitrogen gas at subatmospheric pressures. Subsequent quaternization is performed with a tertiary amine of the formula wherein R1 and R2 are each lower alkyl, and R3 is aliphatic alkyl having 8 to 22 carbons. In a specific embodiment, the quaternizing agent is dimethylcetylamine. When incorporated into skin and hair care compositions, the resulting product exhibits surprising shine and conditioning properties, and provides essential fatty acids for biological maintenance and repair of skin and hair.
The present disclosure provides a microneedle array for administering various drugs, a microneedle structure including the microneedle array, a method of fabricating the microneedle array, and a method of fabricating the microneedle structure. The microneedle array of the present disclosure includes a plurality of microneedles, the surfaces of which are coated with a liquid drug and a base for supporting the microneedles. According to the present disclosure, the microneedles are divided into two or more areas, and the surfaces of microneedles disposed in each of the divided areas are coated with different liquid drugs. In this case, the ingredient of a liquid drug coated on microneedles disposed in one of the divided areas is different from the ingredients of liquid drugs coated on microneedles disposed in the remainder of the divided areas. 
     The microneedle structure of the present disclosure includes a plurality of microneedle arrays, some of the surfaces of which are coated with a liquid drug and a body for supporting the microneedle arrays. According to the present disclosure, the microneedle arrays are coupled to the body so that the microneedle arrays are divided into two or more areas, and the microneedle arrays are coated with different liquid drugs. In this case, the ingredient of a liquid drug coated on at least one of the microneedle arrays is different from the ingredients of liquid drugs coated on the remainder of the microneedle arrays.
A method for making functionalized porous crosslinked polysaccharide gel coated structures used as liquid chromatography media is provided. The method includes impregnating a porous substrate with a room temperature stable aqueous polysaccharide solution containing water, 0.1% to 20% of a polysaccharide, 18% to 54% of a gel-inhibiting agent to prevent the gel from re-gelling, and 0.001% to 10% of an anionic fluorosurfactant for optimum solution coatability onto the substrate, each concentration is by total weight of the aqueous solution. Next water is evaporated from the coating, followed by exposing the dehydrated coating to a gelling agent thereby forming a porous polysaccharide gel coated substrate. Next the gel coated substrate is exposed to a crosslinking agent forming a porous crosslinked polysaccharide gel coated substrate. Next, the gel coated substrate is functionalized by contacting the porous polysaccharide gel coated substrate with sodium 3-bromopropanesulfonate, thereby attaching sulfopropyl ligands to the gel coated substrate, resulting in a functionalized porous absorptive polysaccharide gel coated chromatography structure. When the functionalized gel coated chromatography structure is used as liquid chromatography media, and a protein (e.g. lysozyme) containing solution contacts the media, the sulfopropyl ligands attached to the gel coated chromatography structure will bond to the protein, thereby removing the protein from the protein containg solution.
Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition. (A) A content of benzyl benzoate is less than 1% by mass with respect to the entire mass of the pharmaceutical composition. (B) A content of the nonaqueous carrier is 40% to 75% by mass with respect to the entire mass of the pharmaceutical composition.
PURPOSE:A composition for oral cavity such as detifrice, etc. having immediate, improved removing effect on foul breath, promoting salivation, raising self-cleaning action on the oral cavity, obtained by blending a composition for oral cavity with Zedoariae Phizoma or its water-soluble fraction. CONSTITUTION:A composition for oral cavity such as detifrice, e.g., toothpaste, wet toothpaste, tooth powder, etc., cleaner for mouth, paste for oral cavity, throche, chewing gum, tablet for gargling, etc. is blended with (A) Zedoariae Rhizoma or (B) its water-soluble fraction, to give a composition for oral cavity having the above-mentioned acting effect. The component A are fine particles such as powder having <=400mu, especially 10-100mu particle size, or granule, and an amount of it blended is 0.01-80wt%, preferably 0.05-50wt% based on the composition. An amount of the component B blended is 0.001-10wt%, preferably 0.005-5wt% based on the total amounts of the composition, it shows the above-mentioned effects at a relatively low concentration, has little smell, and is light brown, so it does not damage smell and color of the composition.
Diabetes is one of the commonly seen health hazards in modern times. According to statistics, 70% people with diabetes have died of cardiovascular diseases.

Framingham 's study has proven the increase of the congestive heart-failure (2.4:1 in male patients and5:1 in female patients), which has no association with the age, hypertension, obesity, cardiovascular disease and Hyperlipidemia\[1\]. Other prospective studies also showed that the patients with diabetes in the early stage may be subject to abnormal echocardiogram and their probabilities of suffering from heart failure in the lifetime and Q-wave and non-Q wave myocardial infarction will be increased\[1,2\]. Early in 2000, American Heart Association issued a statement that "diabetes is a cardiovascular disease" \[3\]and in 2007, with reference to the joint guidelines concerning diabetes, pre-diabetes and cardiovascular disease, European Society of Cardiology (ESC) and the European Diabetes Research Institute (ESAD) clearly pointed out that hyperglycemia and cardiovascular disease (CVD) are closely related and the danger of CVD can be raised notably for those whose blood glucose is normal when fasting but tend to increase postprandially\[4\]. In the pathogenesis study of cardiovascular complications of diabetes, the promotion of oxidative stress and declination of the heart antioxidant reserves have close associations with the cardiovascular complications in animal and human body\[5\]. A number of cytokines and inflammatory signaling pathways are involved including tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (HsCRP), adiponectin, IL-6, NF-κB\[1,6\]. Accordingly, this study analyzes the echocardiography, high-sensitivity C-reactive protein and tumor necrosis factor-α of the patients with diabetics in our hospital in order to find early warning indicators of the cardiovascular complications of diabetes and provide prevention and treatment for cardiovascular complications of diabetes.
The invention relates to an application of MBL in preparing a medicament for preventing or treating obesity and a method for screening the medicament for preventing or treating obesity, belonging to the technical field of biotechnology and medicine. In the present invention, the serum MBL levels of normal controls and obese patients were studied and it was found that the serum MBL levels of obese patients were significantly lower than normal controls. Mannose-binding lectin gene-deficient mice are obtained by using a gene editing technology, and MBL gene knockout is found to remarkably aggravate blood sugar metabolic disorder of obese mice and increase the volume of fat cells. The MBL inhibition adipocyte differentiation test shows that the MBL can inhibit adipocyte differentiation by down-regulating adipogenic differentiation related genes C/EBP alpha and PPAR gamma. From this, it is known that MBL is closely related to obesity. Therefore, the mannose binding lectin can be used for preparing a medicament for preventing or treating obesity and for preparing a medicament for inhibiting adipogenic differentiation of 3T3-L1 preadipocytes.
Objective: The unrelenting turmoil of the COVID-19 pandemic has been especially hard on those in the healthcare field. This chronic stress has resulted in depleted compassion towards patients served and colleagues. Researchers have suggested that empathy is a finite resource that must be replenished. For physicians in residency training and those in practice, where finding meaning and purpose in their work is already a challenge, the spark for medicine and helping others may easily become extinguished.This article explores interventions implemented in two family medicine residency programs to address concerns about burnout and compassion fatigue exacerbated by the COVID-19 pandemic.Methods: A qualitative research approach is employed here through case studies of two family medicine programs, along with a description of several interventions intended to mitigate burnout and compassion fatigue during the pandemic.Participants were 36 family medicine residents from "residency #1" and 36 family medicine residents from "residency #2."Results: The authors describe several interventions used in the two residency programs to reduce issues of compassion fatigue. These include meditation, gratitude practice, guided group support, and a focus on clinicians' physical health.Feedback from residents and program leaders suggest that these interventions were useful tools to help physicians navigate their new normal as they began to practice during a pandemic, thereby reducing burnout and challenges with compassion fatigue. A strategic plan is outlined to help other programs implement some of these strategies.Conclusions: It is imperative that training programs continue to implement interventions that emphasize resident and post-residency wellness to reduce compassion fatigue in order to navigate the new stressors that came with the COVID-19 pandemic and those that will come with pandemics in the future.
Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.

Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.

There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to this drug may be more pronounced in the elderly.

Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.

Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.

The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs. There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, hexobarbital, phenytoin, allentanil, diisopyramide, lovastatin, and bromocriptine. Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.

Erythromycin significantly alters the metabolism of terfenadine when taken concomitantly. Rare cases of serious cardiovascular adverse events, including death, cardiac arrest, torsades de pointes, and other ventricular arrhythmias, have been observed. (See CONTRAINDICATIONS.)

It has been reported that sulfisoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. This interaction should be kept in mind when erythromycin ethylsuccinate and sulfisoxazole acetyl for oral suspension is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed.

It has been proposed that sulfisoxazole competes with thiopental for plasma protein binding. In one study involving 48 patients, intravenous sulfisoxazole resulted in a decrease in the amount of thiopental required for anesthesia and in a shortening of the awakening time. It is not known whether chronic oral doses of sulfisoxazole have a similar effect. Until more is known about this interaction, physicians should be aware that patients receiving sulfisoxazole might require less thiopental for anesthesia.

Sulfonamides can displace methotrexate from plasma protein binding sites, thus increasing free methotrexate concentrations. Studies in man have shown sulfisoxazole infusions to decrease plasma protein-bound methotrexate by one fourth.

Sulfisoxazole can also potentiate the blood-sugar-lowering activity of sulfonylureas.
Gastric cancer (GC) is an aggressive malignancy; 5.0% of GC patients are diagnosed before the age of 40. These patients are more aggressive and advanced stage at the diagnosis. Microsatellite instability-high (MSI-H) status is usually seen in relatively older patients. We report a 31-year-old male patient presenting with an intra-abdominal mass and spleen lesions that radiologically mimic a gastrointestinal stromal tumor (GIST). He underwent surgery. Histological examination revealed poorly differentiated adenocarcinoma starting from the deep gastric mucosa. After surgery, rapidly progressive disease was observed. The patient with MSI-H and combined positive score (CPS) of 65% was treated with a combination of immunotherapy and chemotherapy; complete response was observed in approximately 3 months. This is a very rare GC case in young adult age with MSI-H status and responds to treatment in a short time. Predictive markers for immunotherapy efficacy are still being discussed; this case supports the predictive role of high CPS score and MSI-H phenotype in demonstrating treatment efficacy.
The invention discloses a dendrobium manufacturing method. In the processing process, the fresh dendrobium is screened in advance, the dendrobium is screened before processing, and thus the workload of sorting is largely reduced. The temperature for softening dendrobium is 12 DEG C, and the dendrobium is softened at a high temperature for the first time so as to remove the most water of the dendrobium. The temperature for secondary softening of dendrobium is 8 DEG C, because the water content of the dendrobium is largely reduced, the secondary softening can be carried out at a lower temperature, and at the same time the dendrobium can be protected from being burnt. The time for secondary ventilation of dendrobium is two days, the secondary ventilation is close to the end of the manufacturing method, long time ventilation can further dry the dendrobium, and thus the preservation time of dendrobium is prolonged. In the secondary baking of dendrobium, the dendrobium is baked at gradient temperatures and times to produce finished dendrobium product so as to radically remove the water content of dendrobium, at the same time the dendrobium is sterilized and disinfected, and the coking due to dryness is prevented.
PURPOSE:To provide a rememdy for acne vulgaris, containing pantethine, and capable of inhibiting the activation of lipid, contributing to the normalization of the sebum composition, and suppressing the tylosis of the cuticle cell membrane caused by the abnormality in the cuticle. CONSTITUTION:The objective remedy for acne vulgaris contains pantethine. Pantethine is known as lipid metabolism improving agent for oral administration. By the external application, pantethine exhibits moisture-retaining effect to the cuticle, inhibits the activation of lipid, contributes to the normalization of the sebum composition, suppresses the tylosis of the cuticle cell membrane caused by the abnormality in the cuticle, and acts effectively to any stages of a dermatopathy (acne vulgaris) by the synergistic effect of the above activities. For the above purpose, pantethine is applied in the form of e.g. cream, gel, lotion, etc. The content of pantethine in the preparation is usually 1-10%.
PROBLEM TO BE SOLVED: To obtain an aqueous medicine comprising a sulfonamide solubilized in weak acidity to a pH in the vicinity of neutrality. SOLUTION: This aqueous medicine comprises a sulfonamide, a polyvinyl pyrrolidone and a cyclodextrin in which the sulfonamide is solubilized in weak acidity to neutrality, especially at pH3-7.5 in which the sulfonamide is extremely difficult to be dissolved in water. Sulfadiazine, sodium sulfisomidine, etc., in >=1W/V% are used as the solfonamide. A straight-chain polyvinyl pyrrolidone having 10,000-700,000 molecular weight in 0.5-10W/V% concentration is used as the polyvinyl pyrrolidone. A cyclodextrin selected from α, β and γ- cyclodextrins in 1-8W/V% concentration is used as the cyclodextrin. The product of the concentration of the polyvinyl pyrrolidone and that of the cyclodextrin is >=4[W/V%]<2> . The aqueous medicine containing the sulfonamide is useful as an external agent, an eye drop, a nasal drop, an ear drop, etc.
Teriflunomide is an oral de novo pyrimidine synthesis inhibitor of the DHO-DH enzyme, with the chemical name (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4-­trifluoromethylphenyl)-amide. Its molecular weight is 270.21, and the empirical formula is C12H9F3N2O2 with the following chemical structure:

Teriflunomide is a white to almost white powder that is sparingly soluble in acetone, slightly soluble in polyethylene glycol and ethanol, very slightly soluble in isopropanol and practically insoluble in water.

Teriflunomide is formulated as film-coated tablets for oral administration. Teriflunomide tablets contain 14 mg of teriflunomide and the following inactive ingredients: lactose monohydrate, hydroxypropylcellulose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The film coating for the 14 mg tablet is made of titanium dioxide, talcum, hypromellose, cottonseed oil and FD&C Blue no. 2 Al-Lake and FD&C Red No. 40.
OBJECTIVE: In recent years, the clinical efficacy of medications for adenoid hypertrophy has been demonstrated. Topical nasal steroids have effects to shrink hypertrophic adenoids and improve symptoms of associated diseases. However, the mechanism which topical steroid administrations cause adenoid shrinkage remains unclear, herein, sensitivity for topical steroids in the mucosal epithelium of adenoids was evaluated histologically by comparing with tonsils.
METHODS: Histological analysis was performed on adenoids and tonsils removed from 32 pediatric patients with adenoid hypertrophy. In hematoxylin-eosin-stained specimens, the morphology of the mucosal epithelium and eosinophil infiltration were evaluated. The expression of the glucocorticoid receptor (GR), interleukin (IL)-4, and IL-25 in the mucosal epithelium was evaluated, and the staining intensity was scored as 0 (none), 1 (weak), and 2 (strong). The number of eosinophils and expression scores of GR, IL-4, and IL-25 were statistically compared between adenoids and tonsils and analyzed correlations with adenoids sizes.
RESULTS: Adenoids were covered with ciliated epithelium, and eosinophils in the mucosal epithelium and submucosal area was higher than tonsils (p < 0.05). GR expression in the most superficial layer of the mucosal epithelium was observed in adenoids, and the expression intensity score was higher than that in tonsils (p < 0.05). IL-4 and IL-25 were more widely expressed in the mucosal epithelium of adenoids than in tonsils, and their expression intensity scores were also higher than in tonsils (p < 0.05). A correlation was found between adenoid size and the intensity of IL-25 expression in the adenoid epithelium (p < 0.05).
CONCLUSION: Eosinophilic inflammations in adenoids mucosal epithelium could be one of etiology of adenoid hypertrophy, and the GR and eosinophilic inflammation in the adenoids mucosal epithelium might be target of topical nasal steroids to shrink hypertrophic adenoids.
Advanced esophageal and gastric cancer (AEGC) have ranked in the top 10 cancer-related cause of death worldwide, with approximately one million new cases each year. Over half of new cases are in East Asia. The traditional chemotherapy for AEGC remains on intravenous (IV) fluorouracil (5-FU), cisplatin, and the anthracyclines. Trials favoured the combined use of 5-FU and cisplatin for superior efficacy and quality of life in AEGC patients. Recent years, oral chemotherapy has a more practical and economic advantages over IV regimen. It is understandable that patients prefer oral regimens as long as the clinical efficacy is maintained. Oral treatment strategy preserves quality of life for AEGC patients. In addition, it may also have additional cost saving in the nursing and pharmacy time. It is because a significant amount of time can be saved in both nursing and pharmacy for the preparation and administration of IV chemotherapy However, there is a lack of local data to demonstrate the impact of pharmacy and nursing care utilizing capecitabine-based regimen comparing to traditional IV chemotherapy in MCRC patients of Hong Kong.